Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study,Clinical Gastroenterology and Hepatology

当前位置： X-MOL 学术 › Clin. Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study
Clinical Gastroenterology and Hepatology ( IF 11.6 ) Pub Date : 2024-10-28 , DOI: 10.1016/j.cgh.2024.07.048
Megan M.L. Engels, Calise K. Berger, Douglas W. Mahoney, Sanne A. Hoogenboom, Dhruv Sarwal, Derk C.F. Klatte, Jaime De La Fuente, Sonal Gandhi, William R. Taylor, Patrick H. Foote, Karen A. Doering, Adriana M. Delgado, Kelli N. Burger, Barham K. Abu Dayyeh, Aliana Bofill-Garcia, Bhaumik Brahmbhatt, Vinay Chandrasekhara, Ferga C. Gleeson, Victoria Gomez, Vivek Kumbhari, Ryan J. Law, Frank J. Lukens, Massimo Raimondo, Elizabeth Rajan, Andrew C. Storm, Eric J. Vargas Valls, Jeanin E. van Hooft, Michael B. Wallace, John B. Kisiel, Shounak Majumder

In previous studies, methylated DNA markers (MDMs) have been identified in pancreatic juice (PJ) for detecting pancreatic ductal adenocarcinoma (PDAC). In this prospective multicenter study, the sensitivity and specificity characteristics of this panel of PJ-MDMs was evaluated standalone and in combination with plasma carbohydrate antigen 19-9 (CA 19-9).

中文翻译：

使用胰液和血浆 CA 19-9 中的甲基化 DNA 生物标志物进行多模式胰腺癌检测：一项前瞻性多中心研究

在以前的研究中，已在胰液（PJ）中鉴定出甲基化 DNA 标志物（MDM）用于检测胰腺导管腺癌（PDAC）。在这项前瞻性多中心研究中，单独评估了这组 PJ-MDMs 的敏感性和特异性特征，并与血浆碳水化合物抗原 19-9 （CA 19-9）联合评估。

更新日期：2024-10-28

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南